FI974172A0 - B-adrenergisiä agonisteja - Google Patents

B-adrenergisiä agonisteja

Info

Publication number
FI974172A0
FI974172A0 FI974172A FI974172A FI974172A0 FI 974172 A0 FI974172 A0 FI 974172A0 FI 974172 A FI974172 A FI 974172A FI 974172 A FI974172 A FI 974172A FI 974172 A0 FI974172 A0 FI 974172A0
Authority
FI
Finland
Prior art keywords
adrenergic agonists
adrenergic
agonists
Prior art date
Application number
FI974172A
Other languages
English (en)
Swedish (sv)
Other versions
FI974172A (fi
Inventor
Robert L Dow
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI974172A0 publication Critical patent/FI974172A0/fi
Publication of FI974172A publication Critical patent/FI974172A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
FI974172A 1995-05-10 1997-11-07 B-adrenergisiä agonisteja FI974172A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002220399A CA2220399A1 (en) 1995-05-10 1995-05-10 .beta.-adrenergic agonists
PCT/IB1995/000344 WO1996035671A1 (en) 1995-05-10 1995-05-10 β-ADRENERGIC AGONISTS
HU9601240A HUP9601240A1 (en) 1995-05-10 1996-05-09 Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates

Publications (2)

Publication Number Publication Date
FI974172A0 true FI974172A0 (fi) 1997-11-07
FI974172A FI974172A (fi) 1997-11-07

Family

ID=89993954

Family Applications (1)

Application Number Title Priority Date Filing Date
FI974172A FI974172A (fi) 1995-05-10 1997-11-07 B-adrenergisiä agonisteja

Country Status (19)

Country Link
US (1) US5977124A (fi)
EP (1) EP0824519A1 (fi)
JP (1) JPH11504649A (fi)
KR (1) KR100190259B1 (fi)
AU (1) AU706235B2 (fi)
BR (1) BR9602209A (fi)
CA (1) CA2220399A1 (fi)
CO (1) CO4440567A1 (fi)
CZ (1) CZ132196A3 (fi)
FI (1) FI974172A (fi)
HU (1) HUP9601240A1 (fi)
IL (1) IL118115A0 (fi)
MX (1) MX9708621A (fi)
NO (1) NO307049B1 (fi)
NZ (1) NZ286548A (fi)
PL (1) PL314120A1 (fi)
SG (1) SG43365A1 (fi)
TR (1) TR199600358A2 (fi)
WO (1) WO1996035671A1 (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981562A (en) * 1996-01-30 1999-11-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6008361A (en) * 1996-04-09 1999-12-28 Pfizer Inc. Substituted pyridines
US6031105A (en) * 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
EP0938476B1 (en) * 1996-11-14 2006-03-08 Pfizer Inc. Process for substituted pyridines
US6001856A (en) * 1997-06-13 1999-12-14 Pfizer Inc. β-adrenergic agonists to reduce a wasting condition
EP0920864A1 (en) * 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US6657063B1 (en) * 1998-04-30 2003-12-02 Pfizer Inc. Combinations of β3 agonists and growth hormone secretagogues
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
ES2228413T3 (es) 1999-07-23 2005-04-16 Pfizer Products Inc. Productos intermedios y un procedimiento para producir agonistas de receptores beta-adrenergicos.
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
US6451587B1 (en) 1999-09-29 2002-09-17 Pfizer Inc. Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone
US6861444B2 (en) * 2000-04-28 2005-03-01 Asahi Kasei Pharma Corporation Bicyclic compounds
EE200300191A (et) * 2000-10-20 2003-10-15 Pfizer Products Inc. Alfa-arüül-etanoolamiinid ja nende kasutamine beeta-3 adrenergiliste retseptorite agonistidena
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
DOP2003000587A (es) * 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US20050075323A1 (en) * 2003-03-05 2005-04-07 Pfizer Inc Beta3 adrenergic receptor agonists and uses thereof
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
US7375100B2 (en) 2003-06-04 2008-05-20 Pfizer Inc 2-amino-pyridine derivatives useful for the treatment of diseases
KR101071748B1 (ko) * 2003-12-23 2011-10-11 아스텔라스세이야쿠 가부시키가이샤 아미노알콜 유도체
WO2006051373A1 (en) * 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
ATE550031T1 (de) 2005-06-06 2012-04-15 Univ Georgetown Zusammensetzungen und verfahren für die lipomodellierung
BRPI0903206E2 (pt) 2009-09-01 2015-07-28 Da Silva Antonio Carlos Nunes Ett Unidade processadora e método de processamento de fraldas e absorventes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) * 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
DE3278014D1 (en) * 1982-10-01 1988-02-25 Merck & Co Inc Aralkylaminoethanol heterocyclic compounds
CA1287061C (en) * 1986-06-27 1991-07-30 Roche Holding Ltd. Pyridine ethanolamine derivatives
GB8703007D0 (en) * 1987-02-10 1987-03-18 Glaxo Group Ltd Chemical compounds
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5019578A (en) * 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
US5216170A (en) * 1989-01-26 1993-06-01 Bayer Aktiengesellschaft (2-aminopropyl) pyridines useful as intermediates
GB9209076D0 (en) * 1992-04-27 1992-06-10 Ici Plc Chemical compounds
JPH08502278A (ja) * 1992-10-16 1996-03-12 ビイク ネダーラント ベスローテン フェンノートシャップ 置換されたエタノールアミンエステル
EP0677043A1 (en) * 1992-12-29 1995-10-18 Smithkline Beecham Corporation Platelet aggregation inhibiting compounds
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
WO1994025427A1 (en) * 1993-04-26 1994-11-10 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
NZ265692A (en) * 1993-06-14 1997-02-24 Pfizer Indole- and benzofuran- containing hydroxyamines and analogs; pharmaceutical compositions
JPH08165276A (ja) * 1994-12-14 1996-06-25 Dainippon Pharmaceut Co Ltd ２−アルキルアミノ−１−フェニルエタノール誘導体

Also Published As

Publication number Publication date
BR9602209A (pt) 1998-04-07
HUP9601240A1 (en) 1997-09-29
AU5218596A (en) 1996-11-21
TR199600358A2 (tr) 1996-11-21
HU9601240D0 (en) 1996-07-29
AU706235B2 (en) 1999-06-10
WO1996035671A1 (en) 1996-11-14
MX9708621A (es) 1998-02-28
US5977124A (en) 1999-11-02
NO961887L (no) 1996-11-11
CO4440567A1 (es) 1997-05-07
NO961887D0 (no) 1996-05-09
NO307049B1 (no) 2000-01-31
EP0824519A1 (en) 1998-02-25
PL314120A1 (en) 1996-11-12
CZ132196A3 (en) 1997-03-12
IL118115A0 (en) 1996-09-12
KR960041168A (ko) 1996-12-19
KR100190259B1 (ko) 1999-06-01
FI974172A (fi) 1997-11-07
SG43365A1 (en) 1997-10-17
JPH11504649A (ja) 1999-04-27
CA2220399A1 (en) 1996-11-14
NZ286548A (en) 1998-03-25

Similar Documents

Publication Publication Date Title
FI974172A (fi) B-adrenergisiä agonisteja
FI973613A (fi) Aryylisulfonyyliaminohydroksaamihappojohdannaisia
DE69524382D1 (de) Spiralverdrängermaschine
FI974170A (fi) B-adrenergisiä agonisteja
DE69631825D1 (de) Kurbelwellenfräsgerät
BR9605387A (pt) 1-azinil-tetrazolinonas
NO954921L (no) Stigerörsystem
FI1893U1 (fi) Packningsstaell
KR970009914U (ko) 외등이 설치된 정자
KR960030200U (ko) 필통
KR970005654U (ko) 환경캔
FI951528A0 (fi) Tofttrappa; anordning foer stigning fraon vatten i baot
FR2732104B1 (fr) Repose-fleches
NO955062D0 (no) Rörledning
FI1819U1 (fi) Reflektor
FI2195U1 (fi) Marknadsfoeringsstaellning
FI2145U1 (fi) Vobblerfluga
FI2597U1 (fi) Kuumakompostori
FI2397U1 (fi) Termoalusta
FI97309C (fi) Pienoismaakellari
FI2022U1 (fi) Jaktkula
FI2277U1 (fi) Marjanpoimintaharava
FI2102U1 (fi) Raefsa
FI2305U1 (fi) Ruohonkarkotin
FI2083U1 (fi) Jahtlave